Contact
searchSearch
HMP Global
Login

Head & Neck Squamous Cell Carcinoma

Head & Neck Squamous Cell Carcinoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Harold Nathan Tan, MD
Videos
Early-Phase Immunotherapy Demonstrates Modest Activity in Recurrent or Metastatic Head and Neck Cancer
07/28/2026
Harold Nathan Tan, MD
Harold Nathan Tan, MD, discusses findings from a retrospective analysis of early-phase immunotherapy trials in recurrent or metastatic head and neck squamous cell carcinoma, highlighting the clinical activity of bispecific antibodies and the...
Harold Nathan Tan, MD, discusses findings from a retrospective analysis of early-phase immunotherapy trials in recurrent or metastatic head and neck squamous cell carcinoma, highlighting the clinical activity of bispecific antibodies and the...
Harold Nathan Tan, MD, discusses...
07/28/2026
Oncology
Guilherme Rabinowits, MD
Videos
FID-007 Plus Cetuximab Demonstrates Encouraging Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/05/2026
Guilherme Rabinowits, MD
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD,...
06/05/2026
Oncology
Anastasios Maniakas, MD, PhD
Videos
ASP-1929 Photoimmunotherapy Demonstrates Clinical Benefit in Recurrent Head and Neck Squamous Cell Carcinoma
06/05/2026
Anastasios Maniakas, MD, PhD
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD,...
06/05/2026
Oncology
Barbara Burtness, MD, FASCO
Videos
Amivantamab Demonstrates Durable Responses in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
06/05/2026
Barbara Burtness, MD, FASCO
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO,...
06/05/2026
Oncology
Glenn Hanna, MD
Videos
Emi-Le Demonstrates Promising Activity in Aggressive Adenoid Cystic Carcinoma
06/01/2026
Glenn Hanna, MD
Glenn Hanna, MD, discusses promising phase 1 results for emiltatug ledadotin (Emi-Le; XMT-1660), a novel B7-H4-directed antibody-drug conjugate that demonstrated encouraging efficacy and a favorable safety profile in patients with aggressive...
Glenn Hanna, MD, discusses promising phase 1 results for emiltatug ledadotin (Emi-Le; XMT-1660), a novel B7-H4-directed antibody-drug conjugate that demonstrated encouraging efficacy and a favorable safety profile in patients with aggressive...
Glenn Hanna, MD, discusses...
06/01/2026
Oncology
Sai-Wei Huang, MD
Videos
Metabolic Subtyping Predicts Immunotherapy Response in Nasopharyngeal Carcinoma
05/13/2026
Sai-Wei Huang, MD
Sai-Wei Huang, MD, discusses findings from a study evaluating metabolic biomarkers in patients with nasopharyngeal carcinoma using RNA sequencing.
Sai-Wei Huang, MD, discusses findings from a study evaluating metabolic biomarkers in patients with nasopharyngeal carcinoma using RNA sequencing.
Sai-Wei Huang, MD, discusses...
05/13/2026
Oncology
Catherine Haring, MD
Videos
Using ctDNA to Guide Treatment in HPV-Positive Oropharyngeal Cancer
04/29/2026
Catherine Haring, MD
Catherine Haring, MD, discusses findings from a study evaluating ctDNA as a biomarker in patients with HPV-related oropharyngeal cancer undergoing surgery.
Catherine Haring, MD, discusses findings from a study evaluating ctDNA as a biomarker in patients with HPV-related oropharyngeal cancer undergoing surgery.
Catherine Haring, MD, discusses...
04/29/2026
Oncology
Annu Singh, MD
Videos
IMRT and Proton Therapy Demonstrate Comparable Osteoradionecrosis Risk in Oral Cavity Cancer
03/17/2026
Annu Singh, MD
Annu Singh, MD, discusses a retrospective study showing that IMRT and proton therapy were associated with similar rates of osteoradionecrosis after postoperative treatment for oral cavity cancer, while mandibular surgery and radiation dose...
Annu Singh, MD, discusses a retrospective study showing that IMRT and proton therapy were associated with similar rates of osteoradionecrosis after postoperative treatment for oral cavity cancer, while mandibular surgery and radiation dose...
Annu Singh, MD, discusses a...
03/17/2026
Oncology
Edward Christopher Dee, MD
Videos
Radiation Modality Influences Risk of Osteoradionecrosis in Head and Neck Cancer
03/17/2026
Edward Christopher Dee, MD
Edward Christopher Dee, MD, discusses results from a retrospective study showing that proton therapy was associated with a higher incidence of any-grade osteoradionecrosis than intensity-modulated radiotherapy in patients with oropharyngeal...
Edward Christopher Dee, MD, discusses results from a retrospective study showing that proton therapy was associated with a higher incidence of any-grade osteoradionecrosis than intensity-modulated radiotherapy in patients with oropharyngeal...
Edward Christopher Dee, MD,...
03/17/2026
Oncology
Ranee Mehra, MD
Videos
OrigAMI-4 Demonstrates Encouraging Activity of Subcutaneous Amivantamab Plus Pembrolizumab in HPV-Negative Head and Neck Cancer
03/05/2026
Ranee Mehra, MD
Ranee Mehra, MD, discusses results from the phase 1b/2 OrigAMI-4 trial showing that subcutaneous amivantamab plus pembrolizumab demonstrated encouraging antitumor activity and promising early outcomes in patients with recurrent or metastatic...
Ranee Mehra, MD, discusses results from the phase 1b/2 OrigAMI-4 trial showing that subcutaneous amivantamab plus pembrolizumab demonstrated encouraging antitumor activity and promising early outcomes in patients with recurrent or metastatic...
Ranee Mehra, MD, discusses...
03/05/2026
Oncology

Recent News

FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology
News
Izalontamab Brengitecan Shows Promising Clinical Activity in Previously Treated Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from a phase 1b dose-expansion study demonstrated that izalontamab brengitecan, a bispecific antibody-drug conjugate targeting EGFR and HER3, produced encouraging antitumor activity in patients with relapsed extensive-stage small cell...
Results from a phase 1b dose-expansion study demonstrated that izalontamab brengitecan, a bispecific antibody-drug conjugate targeting EGFR and HER3, produced encouraging antitumor activity in patients with relapsed extensive-stage small cell...
Results from a phase 1b...
07/28/2026
Oncology
News
Advanced Age Does Not Compromise Azacitidine Outcomes in Higher-Risk Myelodysplastic Syndromes
07/27/2026
Emily Estrada
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective,...
07/27/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use